-
FDA approved 4 innovative drugs to be launched!
Time of Update: 2021-10-22
Source: Yaorongyun Global Drug Research and Development Database Tivdak's first ADC therapy for cervical cancerTivdak's first ADC therapy for cervical cancer On September 20, the United States (FDA) accelerated the approval of Seagen's ADC drug Tivdak (Tisotumab vedotin) for the treatment of recurrent or metastatic cervical cancer .
-
Trading frenzy in the neuroscience field is repeated, and top venture capitalists join forces with Amgen to establish a new company for US$500 million
Time of Update: 2021-10-22
Amgen announced in 2019 that it would abandon drug research in the neuroscience field, so there are many potential drug molecules in the pipeline for Neumora to choose from .
-
FDA's first batch of drugs will be ushered in in the fourth quarter of 2021
Time of Update: 2021-10-22
In June 2021, the FDA accepted pacritinib for the treatment of NDA for myelofibrosis with severe thrombocytopenia, and granted the application priority review.
In May 2021, Takeda announced that the FDA will accept maribavir treatment of refractory, with or without drug-resistant CMV infection NDA, and grant the application priority review .
-
Sword refers to the "king of cancer", a variety of KRAS inhibitors show anti-cancer activity
Time of Update: 2021-10-22
At the AACR-NCI-EORTC Molecular Targets and Cancer Treatment Conference held last weekend, a number of companies announced the latest results of KRAS inhibitors under development.
aspx[3] Mirati Therapeutics to Present New Research From its Innovative Oncology Pipeline at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer.
-
Brief comment on domestic orthopedics product line
Time of Update: 2021-10-22
With the rise of biological drug R&D and promotion, domestic pharmaceutical companies' R&D for orthopedic products is mainly concentrated in the field of rheumatoid arthritis .
-
AstraZeneca Global R&D China Center officially opened
Time of Update: 2021-10-21
On October 11, AstraZeneca, the world's leading multinational pharmaceutical company, announced the official opening of its Global R&D China Center in Jing'an District, Shanghai .
-
Encourage the R&D and production of children's medications through multiple measures-to meet medication needs and ensure medication safety
Time of Update: 2021-10-21
Open the green channel for review and approval Adhere to child-centered and clinical needs-oriented, high standards, strict requirements, and strong services to ensure that the quality of drugs after the market is guaranteed Not long ago, entecavir granules for children developed by a pharmaceutical company in Hunan were approved for marketing, and children with hepatitis B have special drugs .
-
Benchmark Medical/Twist Bioscience pan-cancer methylation products are launched globally
Time of Update: 2021-10-21
Reference materials:Reference materials: [1] The pan-cancer methylation product jointly developed by Benchmark Medical and Twist Bioscience is launched globally.
from https:// The pan-cancer methylation product jointly developed by Benchmark Medical and Twist Bioscience is launched globally.
-
8 pharmaceutical companies!
Time of Update: 2021-10-21
On October 11, the Ministry of Industry and Information Technology announced the list of national technological innovation demonstration enterprises to be recognized in 2021 . It is planned to iden
-
New opportunities for innovative drug research and development in September 2021
Time of Update: 2021-10-21
TNK1 inhibitor On September 9, 2021, researchers from Brigham Young University and Sumitomo Dainippon Pharma reported on the new anti-cancer target TNK1 on Nat Commun, and developed a small molecule inhibitor TP-5801 .
-
[Authoritative release] National Health Commission and Zhejiang Provincial Government jointly create a provincial demonstration of high-quality development
Time of Update: 2021-10-21
Support Zhejiang Province in launching a national pilot project for innovation in the system and mechanism of basic-level children's medical and health care services, take the lead in building a three-in-one child health management center of "medicine, prevention, and nursing", establish an effective referral mechanism, and promote the in-depth integration of child health and diagnosis and treatment services .
-
The "Giant Whale" is swinging its tail and the industry is turning-where will the "new golden decade" of China's innovative drugs go?
Time of Update: 2021-10-21
Under the influence and stimulus of policies and domestic and foreign markets, it is foreseeable that the ten years starting from July 2021 will be an important period for China's innovative drugs to upgrade internally, radiate outward, and the entire industrialization of cocoons to become butterflies .
-
Today, Sanofi's "clopidogrel aspirin tablets" was approved in China
Time of Update: 2021-10-21
The antiplatelet effect is not inferior to single-agent combination therapy, and the tolerability is equivalent According to the consensus, in addition to efficacy, the special process of clopidogrel/aspirin single-tablet compound preparation can also reduce adverse reactions .
-
BeiGene Baiyueze® (Zebutinib) was approved for the treatment of mantle cell lymphoma
Time of Update: 2021-10-21
On October 11, BeiGene announced that Baiyueze® (Zebutinib) has been approved in Australia for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least one therapy .
-
Today, Heyu Pharmaceutical is officially listed on the Hong Kong Stock Exchange
Time of Update: 2021-10-21
Pan-FGFR inhibitors targeting specific FGFR subtypes of FGFR inhibitors A new generation of FGFR inhibitors ABSK011 : Highly selective FGFR4 small molecule oral inhibitor developed by Heyu Medicine , which can inhibit the growth of tumors by inhibiting the activity of FGFR4 and blocking related signal transduction .
-
The development of commercial insurance needs to grasp the "3 degrees"
Time of Update: 2021-10-21
On the basis of providing basic medical insurance services, how to better encourage and support the development of commercial health insurance is a major issue for the Healthy China strategy and the construction of China's multi-level medical security system .
-
Revealed: 31 drugs or therapies around the world won the Nobel Prize. What is the next Nobel Prize for "New Drug Research and Development"?
Time of Update: 2021-10-21
For example, the 2019 Nobel Prize in Physiology or Medicine is awarded to scientists who have made important contributions in the field of oxygen sensing pathway research .
-
The Center for Drug Appraisal holds an expert seminar on hot topics in children's drug R&D
Time of Update: 2021-10-21
Kong Fanpu emphasized that enterprises are the main body of drug research and development and the core force to solve the problem of shortage of drugs for children in China .
-
Exploration and Thoughts on the Price Formation Mechanism of Innovative Drugs
Time of Update: 2021-10-21
Through national talks, the price reduction of innovative drugs to achieve medical insurance access and speed up the commercialization process is of great significance for improving accessibility .
-
Sales of large varieties soared by 1300%, Qilu first imitated listing
Time of Update: 2021-10-21
The only domestic company that has a layout to imitate ceftazidime and Avibactam sodium for injection, Qilu Pharmaceutical may quickly occupy the market 01.
The launch of Qilu Pharmaceutical's ceftazidime and avibactam sodium for injection may inject new impetus into the treatment of drug-resistant bacteria in China .
